http://www.cnr.it/ontology/cnr/individuo/prodotto/ID276396

11C-Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. (Articolo in rivista)

Type

Articolo in rivista (Classe)
Prodotto della ricerca (Classe)

Label

11C-Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. (Articolo in rivista) (literal)

Anno

2014-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

10.2967/jnumed.113.123380 (literal)

Alternative label

Giampiero Giovacchini 1,2; Maria Picchio 3; Rita Garcia-Parra 4; Alberto Briganti 5; Firas Abdollah 5; Luigi Gianolli 3; Christian Schindler 6; Francesco Montorsi 5; Cristina Messa 4,7,8; and Ferruccio Fazio 3,4 (2014)
11C-Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy.
in The Journal of nuclear medicine (1978)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Giampiero Giovacchini 1,2; Maria Picchio 3; Rita Garcia-Parra 4; Alberto Briganti 5; Firas Abdollah 5; Luigi Gianolli 3; Christian Schindler 6; Francesco Montorsi 5; Cristina Messa 4,7,8; and Ferruccio Fazio 3,4 (literal)

Pagina fine

233 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

Pubblicato on-line: 9 Gennaio 2014 IF 2012: 5.774 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

55 (literal)

Rivista

?The ?Journal of nuclear medicine (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

241 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

2 (literal)

Note

PubMe (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1. Department of Radiology, Stadtspital Triemli, Zurich, Switzerland. 2. Department of Radiology and Nuclear Medicine, Stadtspital Waid, Zurich, Switzerland. 3. Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy. 4. Department of Health Sciences, Tecnomed Foundation, University of Milano-Bicocca, Milan, Italy. 5. Department of Urology, San Raffaele Scientific Institute, Milan, Italy. 6. Swiss Tropical and Public Health Institute, Basel, Switzerland. 7. Institute for Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate (MI), Italy 8. Department of Nuclear Medicine, San Gerardo Hospital, Monza, Italy (literal)

Titolo

11C-Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. (literal)

Abstract

Several studies have shown that 11C-choline PET/CT may be useful for restaging prostate cancer (PCa) patients with biochemical failure after radical prostatectomy. However, validation of 11C-choline PET/CT findings scarcely relied on histologic findings, and prognostic implications of 11C-choline PET/CT are currently unknown. The aim of this study was to assess whether 11C-choline PET/CT predicts survival in PCa patients. METHODS: This retrospective study included 195 PCa patients treated with radical prostatectomy who underwent 11C-choline PET/CT from December 1, 2004, to July 31, 2007, due to biochemical failure (prostate-specific antigen > 0.2 mg/mL) during androgen-deprivation therapy. PCa-specific survival was computed as the interval from radical prostatectomy to PCa-specific death. RESULTS: The median interval after radical prostatectomy was 8.9 y (95% confidence interval [CI], 1.7-18.9 y). The median follow-up after 11C-choline PET/CT was 4.5 y (95% CI, 0.4-8.5 y). 11C-choline PET/CT results were positive in 57% of patients. The median PCa-specific survival was 16.4 y (95% CI, 14.0-18.8 y) in patients with negative 11C-choline PET/CT results and 11.2 y (95% CI, 9.8-12.6 y) in patients with positive 11C-choline PET/CT results (log-rank: ?2 = 19.3, P < 0001). At multivariate analysis, statistical significance was obtained for 11C-choline PET/CT (hazard ratio, 2.53; 95% CI, 1.41-4.53; P = 0.002), prostate-specific antigen (hazard ratio, 1.03; 95% CI, 1.00-1.05; P = 0.037), and Gleason score (>7: hazard ratio, 2.49; 95% CI, 1.25-4.95; P = 0.009). Patients with pathologic 11C-choline uptake in the prostatic bed or in pelvic or retroperitoneal lymph nodes had longer PCa-specific survival (median, 12.1 y; 95% CI, 10.5-13.7 y) in comparison to patients with pathologic tracer uptake in the skeleton (median, 9.9 y; 95% CI, 6.8-13.1 y) (log-rank: ?2 = 6.5, P = 0.010). Two internally validated nomograms predicted 10- and 15-y PCa-specific survival probability with an accuracy of 76% and 74%, respectively. In an ancillary analysis, we also showed that 11C-choline PET/CT predicts PCa-specific survival after PET/CT, with similar statistical power. CONCLUSION: 11C-choline PET/CT predicts PCa-specific survival in PCa patients treated with radical prostatectomy who develop biochemical failure during androgen-deprivation therapy. If independent or multicenter confirmation of these findings is obtained, 11C-choline PET/CT might be more widely used in the follow-up of PCa patients for tailoring salvage therapy. (literal)

Prodotto di